SCHEMBL8075419

SCHEMBL8075419

CCCCCCCCC(N)C(N)CC

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 1/20 0.52
CYP2D6 P10635 2/20 0.50
SPHK1 Q9NYA1 2/20 0.50
LMNA P02545 2/20 0.50
TP53 P04637 2/20 0.50
GMNN O75496 1/20 0.50
POLB P06746 1/20 0.50
THPO P40225 1/20 0.50
MTOR P42345 1/20 0.50
BLM P54132 1/20 0.50
KDM4E B2RXH2 1/20 0.50
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50
MAPT P10636 1/20 0.50
CETP P11597 1/20 0.50
HTT P42858 1/20 0.50
UBE2N P61088 1/20 0.50
LAP3 P28838 2/20 0.45
PLA2G1B P04054 1/20 0.45
PLA2G2A P14555 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1576771 1.00 OPRM1 (0.52) OPRM1CYP2D6SPHK1LMNATP53
SCHEMBL10813760 1.00 OPRM1 (0.52) OPRM1CYP2D6SPHK1LMNATP53
SCHEMBL11088411 1.00 OPRM1 (0.52) OPRM1CYP2D6SPHK1LMNATP53
SCHEMBL10809566 1.00 OPRM1 (0.52) OPRM1CYP2D6SPHK1LMNATP53
SCHEMBL10813214 1.00 OPRM1 (0.52) OPRM1CYP2D6SPHK1LMNATP53
SCHEMBL27309929 0.97 OPRM1 (0.50) OPRM1CYP2D6SPHK1LMNATP53
SCHEMBL11095199 0.97 OPRM1 (0.55) OPRM1CYP2D6SPHK1LMNATP53
SCHEMBL24017118 0.92 OPRM1 (0.60) OPRM1CYP2D6SPHK1LMNATP53
SCHEMBL11454917 0.92 OPRM1 (0.60) OPRM1CYP2D6SPHK1LMNATP53
SCHEMBL8934995 0.92 OPRM1 (0.60) OPRM1CYP2D6SPHK1LMNATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0519406-B1 Magnetic recording media using perfluoropolyether derivatives as lubricants SONY CORP (JP) 2000-10-25 EP claimed
US-20120165519-A1 Fused Bicyclic Derivatives of 2,4-Diaminopyrimidine as ALK and c-MET Inhibitors CEPHALON, INC. (US) 2012-06-28 US disclosed
EP-0519406-B1 Magnetic recording media using perfluoropolyether derivatives as lubricants SONY CORP (JP) 2000-10-25 EP disclosed
US-5536425-A DURABILITY SONY CORPORATION (JP) 1996-07-16 US disclosed
US-5453539-A Durability SONY CORPORATION (JP) 1995-09-26 US disclosed
EP-0519406-A2 Novel perfluoropolyether derivatives, and lubricants and magnetic recording medium using the same SONY CORPORATION (JP) 1992-12-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120165519-A1 Fused Bicyclic Derivatives of 2,4-Diaminopyrimidine as ALK and c-MET Inhibitors ALK, MET, RET OPRM1 1902/4885CYP2D6 1017/4885SPHK1 1659/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.